CA2893318A1 - Thienopyridine derivatives for the treatment and prevention of dengue virus infections - Google Patents
Thienopyridine derivatives for the treatment and prevention of dengue virus infections Download PDFInfo
- Publication number
- CA2893318A1 CA2893318A1 CA2893318A CA2893318A CA2893318A1 CA 2893318 A1 CA2893318 A1 CA 2893318A1 CA 2893318 A CA2893318 A CA 2893318A CA 2893318 A CA2893318 A CA 2893318A CA 2893318 A1 CA2893318 A1 CA 2893318A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- thieno
- pyridine
- carboxamide
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/708,224 | 2012-12-07 | ||
| US13/708,224 US20130129677A1 (en) | 2009-02-27 | 2012-12-07 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
| PCT/US2013/073449 WO2014089378A1 (en) | 2012-12-07 | 2013-12-06 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2893318A1 true CA2893318A1 (en) | 2014-06-12 |
Family
ID=50884015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2893318A Abandoned CA2893318A1 (en) | 2012-12-07 | 2013-12-06 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2928470A4 (enExample) |
| JP (1) | JP2016501883A (enExample) |
| CA (1) | CA2893318A1 (enExample) |
| WO (1) | WO2014089378A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418635A (zh) * | 2015-12-25 | 2016-03-23 | 上海应用技术学院 | 一种噻吩并吡啶类医药中间体的合成方法 |
| CN105832734B (zh) * | 2016-03-31 | 2018-05-04 | 南通江海港建设工程有限公司 | 一种化合物在增加血小板浓度药物中的用途 |
| CN105769866B (zh) * | 2016-03-31 | 2018-05-04 | 南通江海港建设工程有限公司 | 一种化合物在增加血小板浓度药物中的用途 |
| JP7041877B2 (ja) * | 2016-06-14 | 2022-03-25 | 国立大学法人 東京大学 | チエノ［２，３－ｂ］ピリジン誘導体およびキノリン誘導体ならびにそれらの使用 |
| SG11202003807RA (en) | 2017-11-03 | 2020-05-28 | Univ Montreal | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
| US20210230179A1 (en) * | 2018-06-06 | 2021-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Thieno[2,3-b]pyridine derivatives as epac inhibitors and their pharmaceutical uses |
| CN115003383B (zh) * | 2019-08-21 | 2024-10-01 | 斯克里普斯研究学院 | 干扰素基因刺激物sting的双环激动剂 |
| WO2021108999A1 (zh) * | 2019-12-03 | 2021-06-10 | 辽宁凯莱英医药化学有限公司 | 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法 |
| CN111072463A (zh) * | 2019-12-03 | 2020-04-28 | 辽宁凯莱英医药化学有限公司 | 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法 |
| WO2021250231A1 (en) * | 2020-06-12 | 2021-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Thienopyridine derivatives for use in the treatment of coronavirus infection |
| WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3533095A (en) * | 1994-09-22 | 1996-04-09 | Rational Drug Design Laboratories | Arylthiadiazole derivative and antiviral agent containing the same |
| GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| US7202363B2 (en) * | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
| AR048669A1 (es) * | 2004-03-03 | 2006-05-17 | Syngenta Ltd | Derivados biciclicos de bisamida |
| SE0403171D0 (sv) * | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
| JP2006298909A (ja) * | 2005-03-25 | 2006-11-02 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007136776A2 (en) * | 2006-05-17 | 2007-11-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pyrimidine low molecular weight ligands for modulating hormone receptors |
| CN104856991A (zh) * | 2009-02-27 | 2015-08-26 | 西佳技术公司 | 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物 |
| US20130129677A1 (en) * | 2009-02-27 | 2013-05-23 | Siga Technologies, Inc. | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections |
| WO2011006158A2 (en) * | 2009-07-10 | 2011-01-13 | University Of Maryland, Baltimore | Targeting nad biosynthesis in bacterial pathogens |
-
2013
- 2013-12-06 EP EP13859644.0A patent/EP2928470A4/en not_active Withdrawn
- 2013-12-06 WO PCT/US2013/073449 patent/WO2014089378A1/en not_active Ceased
- 2013-12-06 JP JP2015545858A patent/JP2016501883A/ja active Pending
- 2013-12-06 CA CA2893318A patent/CA2893318A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014089378A1 (en) | 2014-06-12 |
| EP2928470A1 (en) | 2015-10-14 |
| EP2928470A4 (en) | 2015-12-16 |
| JP2016501883A (ja) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2893318A1 (en) | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | |
| AU2010218152B2 (en) | Thienopyridine derivatives for the treatment and prevention of Dengue virus infections | |
| JP4109271B2 (ja) | 置換されたアリールアシルチオ尿素および関連化合物；ウイルス複製のインヒビター | |
| US20130129677A1 (en) | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | |
| CN104507481B (zh) | 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物 | |
| CA2850976C (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| AU2008256727A1 (en) | Antiviral drugs for treatment or prevention of dengue infection | |
| CA2726985A1 (en) | Small molecule inhibitors for the treatment or prevention of dengue virus infection | |
| AU2010266570A1 (en) | Treatment and prevention of Dengue virus infections | |
| MX2011006514A (es) | Compuesto y metodo de uso. | |
| AU2012322698A1 (en) | 8 - carbamoyl - 2 - (2,3- di substituted pyrid - 6 - yl) -1,2,3,4 -tetrahydroisoquinoline derivatives as apoptosis - inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| TW201350481A (zh) | Ｎａｍｐｔ抑制劑 | |
| US12559497B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| WO2010082044A1 (en) | Unsaturated bicyclic heterocyclic derivatives as smo antagonists | |
| DE102005028077A1 (de) | Alkinyl-substituierte Thiophene | |
| US20070259911A1 (en) | Novel Compounds and Use of Tetrahydropyridothiophenes | |
| US20100285149A1 (en) | Novel tetrahydropyridothiophenes | |
| JP2008526817A (ja) | 新規のピロロジヒドロイソキノリン | |
| AU2015203873A1 (en) | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | |
| US20090209534A1 (en) | Novel compounds and use of tetrahydropyridopyridothiophenes | |
| WO2020177128A1 (zh) | 2,6-二氮杂螺[3.4]辛烷类嘧啶-异羟肟酸化合物及其用途 | |
| US20130053396A1 (en) | Piperidine and piperazine derivatives as smo antagonists | |
| WO2012109573A1 (en) | Substituted thiazoles for use as antiviral agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20181206 |